Upstream Bio Inc
NASDAQ:UPB

Watchlist Manager
Upstream Bio Inc Logo
Upstream Bio Inc
NASDAQ:UPB
Watchlist
Price: 25.87 USD -1% Market Closed
Market Cap: 1.4B USD

Net Margin
Upstream Bio Inc

-4 386.4%
Current
-3 667%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 386.4%
=
Net Income
-122.8m
/
Revenue
2.8m

Net Margin Across Competitors

No Stocks Found

Upstream Bio Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The firm has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).

UPB Intrinsic Value
0.19 USD
Overvaluation 99%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4 386.4%
=
Net Income
-122.8m
/
Revenue
2.8m
What is the Net Margin of Upstream Bio Inc?

Based on Upstream Bio Inc's most recent financial statements, the company has Net Margin of -4 386.4%.

Back to Top